Treatment options after sorafenib failure in patients with hepatocellular carcinoma

by Imane El Dika, Ghassan K. Abou-Alfa
Published 2017-12-01

Proportion of cancer in a Middle eastern country attributable to established risk factors

by Maya A. Charafeddine, Sara H. Olson, Deborah Mukherji, Sally N. Temraz, Ghassan K. Abou-Alfa, Ali I. Shamseddine
Published 2017-05-01

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

by James J. Harding, Richard K. Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Robin K. Kelley, Ghassan K. Abou‐Alfa
Published 2021-05-01

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

by Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K. Abou-Alfa
Published 2018-03-01

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

by Imane El Dika, Marinela Capanu, Joanne F. Chou, James J. Harding, Michele Ly, Anna D. Hrabovsky, Richard K.G. Do, Jinru Shia, Brittanie Millang, Jennifer Ma, Eileen M. O’Reilly, Ghassan K. Abou‐Alfa
Published 2020-10-01

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

by Arndt Vogel, Lorenza Rimassa, Hui-Chan Sun, Ghassan K. Abou-Alfa, Anthony El-Khoueiry, David J. Pinato, Javier Sanchez Alvarez, Monica Daigl, Panos Orfanos, Michael Leibfried, Marie-Hélène Blanchet Zumofen, Vincent E. Gaillard, Philippe Merle
Published 2021-05-01